Pfizer and KineMed Inc. have renewed a non-exclusive research collaboration for the advancement of new approaches in metabolic disease, namely Type II diabetes. The collaboration employs KineMed’s proteomics technology platform to map the impact of potential drug candidates on specific metabolic pathways.   “We are very pleased to announce the extension of this ongoing partnership in an important area of medicine that affects so many Americans. Our translational biomarker platform targets the me...